Related Experiment Video
Updated: Dec 25, 2025
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?
Pawel Rajwa1, Jamil Syed2, Michael S Leapman3
1Department of Urology, Medical University of Silesia, 41-800, Zabrze, Poland.
Objective:
To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer.
Results:
Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with suspicion of prostate cancer who are considering first-time or repeat biopsy, blood- and urine-based assays can improve the prediction of harboring clinically significant disease and may reduce unnecessary biopsy. Blood- and urine-based biomarkers have been evaluated in association with prostate MRI, offering insights that might augment decision-making in the pre and post-MRI setting. Tissue-based genomic and proteomic assays have also been developed that provide independent assessments of prostate cancer aggressiveness that can complement imaging.
Conclusion:
A growing number of non-imaging biomarkers are available to assist in clinical decision-making for men with known or suspected prostate cancer. An appreciation for the intersection of imaging and biomarkers may improve clinical care and resource utilization for men with prostate cancer.
